MC4R mutations compromise 3%–5% of cases of monogenic obesity in humans, making MC4R signaling and its downstream circuitry an appealing target for obesity therapeutics (Huszar et al., 1997; Lubrano-Berthelier et al., 2006; Bromberg et al., 2009). The gene discussed is MC4R; the disease is obesity disorder.